Sie suchten nach: single blind (Englisch - Maltesisch)

blind
double blind

double blind
double blind

aids for the blind.
mezzi għall-għomja,

african blind barb fish
barbu għami afrikan

blind carps, plaeesok
karpjuni għomja, plaeesok

literature for the blind;
letteratura għall-għomja;

allowances for blind persons
il-benefiċċju ta’ dipendenza

• blind persons' allowances.
• l-għajnuna lill-għomja.

blind spot rear-view mirror
il-mera li turi l-oġġetti moħbija fuq wara

double-blind placebo-controlled studies
studji double-blind ikkontrollati bi plaċebo

is randomised, double-blind, multinational study.
to trasfużjonijiet ta 'ċelluli ħomor tad- demm f' pazjenti li kienu qed jirċievu l- kimoterapija ġew assessjati fi studju randomized, double- blind, multi- nazzjonali.

a single european label would be blind to the particular and outstanding qualities of individual countries' products – "united in diversity".
tikketta unika ewropea ma tagħtix każ tal-kwalitajiet partikolari u ta’ min ifaħħarhom tal-prodotti tal-pajjiżi individwali – ‘uniti fid-diversità’.

during the 4 week single-blind withdrawal period in study 2 (ibs-3002), no evidence of rebound diarrhoea or abdominal pain was demonstrated.
waqt il-perjodu ta’ tneħħija single-blind ta’ 4 ġimgħat fi studju 2 (ibs-3002), ma ntweritx evidenza ta’ dijarea jew uġigħ addominali rebound.

in a single, double blind, placebo controlled study, 161 mdr-tb patients received 8 weeks treatment with delamanid 100 mg twice daily in combination with who recommended individualised obr.
fi studju wieħed bi prova li kienet double blind, ikkontrollat bi plaċebo 161 pazjent b’mdr-tb rċevew trattament għal 8 ġimgħat b’delamanid 100 mg kuljum flimkien ma’ programm ta’ kura obr rakkomandat mill-who b’mod individwali.

randomised, single-blind, single dose, crossover studies in 196 healthy volunteers showed that the pharmacokinetic profile of biograstim was comparable to that of the reference product after subcutaneous and intravenous administration.
studji randomised, single–blind, b’doża waħda u crossover li saru fuq 196 voluntiera b’saħħithom urew li l-profil farmakokinetiku ta’biograstim kien komparabbli ma’ dak tal-prodott ta’ referenza kemm wara amministrazzjoni taħt il-ġilda kif ukoll ġol-vina.

randomised, single-blind, single dose, crossover studies in 196 healthy volunteers showed that the pharmacokinetic profile of filgrastim ratiopharm was comparable to that of the reference product after subcutaneous and intravenous administration.
studji randomised, single-blind, b’doża waħda u crossover li saru fuq 196 voluntiera b’saħħithom urew li l-profil farmakokinetiku ta’filgrastim ratiopharm kien komparabbli ma’ dak tal-prodott ta’ referenza kemm wara amministrazzjoni taħt il-ġilda kif ukoll ġol-vina.

patients fulfilling the oral stabilisation requirement in the oral stabilisation phase were assigned to receive, in a single-blind fashion, abilify maintena and began an abilify maintena stabilisation phase for a minimum of 12 weeks and a maximum of 36 weeks.
pazjenti li ssodisfaw ir-rekwiżit ta’ stabilizzazzjoni orali fil-fażi ta’ stabilizzazzjoni orali kienu assenjati biex jirċievu, b’mod single-blind, abilify maintena u bdew fażi ta’ stabilizzazzjoni fuq abilify maintena għal minimu ta’ 12-il ġimgħa u massimu ta’ 36 ġimgħa.

leflunomide was studied in a single multicenter, randomized, double-blind, active-controlled trial in 94 patients (47 per arm) with polyarticular course juvenile rheumatoid arthritis.
leflunomide kien studjat f’diversi ċentri fi prova waħda, tat-tip randomised, double blind u active- controlled, f’94 pazjent (47 f’kull grupp) li kellhom l-artrite rewmatika taż-żgħażagħ u li nvolviet diversi ġogi tul il-kors tagħha.

in the single-blind study, patients were treated with epoetin alfa 300 iu/kg or 600 iu/kg or placebo intravenously once daily every 3 to 4 days over 3 weeks (total 6 doses).
fl-istudju single-blind, il-pazjenti ġew ikkurati b’epoetin alfa 300 iu/kg jew 600 iu/kg jew plaċebo ġol-vina darba kuljum kull 3 sa 4 ijiem, fuq perjodu ta’ 3 ġimgħat (total ta’ 6 dożi).

double-blind, randomised, placebo-controlled, except for studies c212 and hpc3011 which were open-label, single arm.
la l-investigaturi u lanqas il-pazjenti ma kienu jafu liema sustanza qed tintuża, każwali, kkontrollati bi plaċebo ħlief għall-istudji c212 u hpc3011 fejn kemm l-investigaturi kif ukoll il-pazjenti kienu jafu liema sustanza qed tintuża, u kellhom fergħa waħda.